دليل الناشطين
في الرقميات والتكنولوجيا
الوصف
1. Minimed Medtronic 760G optimizes glucose control in patients with type 1 diabetes mellitus
Evaluated 59 T1D patients, comparing automatic (auto) vs manual modes over intervals from 1 month to over 6 months.
Results: Significant improvements in Time in Range (TIR), glucose variability, HbA1c, and reduced Time Below Range (TBR < 54 mg/dL). No severe hypoglycemia or ketoacidosis was recorded.
PubMed
2. Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 760G in Children, Adolescents and Young Adults: A Systematic Review
Review of 31 studies in individuals under 25 years with T1D.
Metabolic outcomes: HbA1c dropped to around 7%; TIR of 75–80%; TBR and TAR within recommended targets.
Safety: No severe hypoglycemia (SH) or diabetic ketoacidosis (DKA) in most studies.
Psychological outcomes: Improvements in sleep quality, treatment satisfaction, and reduction in emotional burden for patients and caregivers.
PubMed
NCBI
3. Long-term Real‑World Use in Pediatric Population
A real-world study of 111 children/adolescents over up to 24 months:
After switching to auto mode, TIR rose from ~67% to ~76%; TAR levels dropped; variability and mean glucose improved significantly.
Improvements sustained throughout 24 months.
Better outcomes observed when using optimal settings (Active Insulin Time (AIT) of 2 h and SmarGuard target of 100 mg/dL).
Evaluated 59 T1D patients, comparing automatic (auto) vs manual modes over intervals from 1 month to over 6 months.
Results: Significant improvements in Time in Range (TIR), glucose variability, HbA1c, and reduced Time Below Range (TBR < 54 mg/dL). No severe hypoglycemia or ketoacidosis was recorded.
PubMed
2. Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 760G in Children, Adolescents and Young Adults: A Systematic Review
Review of 31 studies in individuals under 25 years with T1D.
Metabolic outcomes: HbA1c dropped to around 7%; TIR of 75–80%; TBR and TAR within recommended targets.
Safety: No severe hypoglycemia (SH) or diabetic ketoacidosis (DKA) in most studies.
Psychological outcomes: Improvements in sleep quality, treatment satisfaction, and reduction in emotional burden for patients and caregivers.
PubMed
NCBI
3. Long-term Real‑World Use in Pediatric Population
A real-world study of 111 children/adolescents over up to 24 months:
After switching to auto mode, TIR rose from ~67% to ~76%; TAR levels dropped; variability and mean glucose improved significantly.
Improvements sustained throughout 24 months.
Better outcomes observed when using optimal settings (Active Insulin Time (AIT) of 2 h and SmarGuard target of 100 mg/dL).
- الفئات: الخدمات المهنية للأفراد
- المنطقة: الجزائر / الجزائر
- وضع في: 02-04-2026 à 07:15:24
